Market closed
Cardiff Oncology/$CRDF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cardiff Oncology
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Ticker
$CRDF
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
33
ISIN
US14147L1089
Website
Cardiff Oncology Metrics
BasicAdvanced
$177M
-
-$0.92
-
-
Price and volume
Market cap
$177M
52-week high
$5.64
52-week low
$2.01
Average daily volume
1.3M
Financial strength
Current ratio
6.223
Quick ratio
6.041
Long term debt to equity
0.903
Total debt to equity
1.913
Management effectiveness
Return on assets (TTM)
-41.00%
Return on equity (TTM)
-74.15%
Valuation
Price to revenue (TTM)
240.68
Price to free cash flow (TTM)
-3.305
Growth
Revenue change (TTM)
-3.77%
Earnings per share change (TTM)
1.99%
3-year revenue growth (CAGR)
17.59%
3-year earnings per share growth (CAGR)
3.02%
What the Analysts think about Cardiff Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cardiff Oncology stock.
Cardiff Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cardiff Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cardiff Oncology News
AllArticlesVideos
Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon
Seeking Alpha·1 week ago
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
GlobeNewsWire·3 weeks ago
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cardiff Oncology stock?
Cardiff Oncology (CRDF) has a market cap of $177M as of May 11, 2025.
What is the P/E ratio for Cardiff Oncology stock?
The price to earnings (P/E) ratio for Cardiff Oncology (CRDF) stock is 0 as of May 11, 2025.
Does Cardiff Oncology stock pay dividends?
No, Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders as of May 11, 2025.
When is the next Cardiff Oncology dividend payment date?
Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiff Oncology?
Cardiff Oncology (CRDF) does not currently have a Beta indicator.